Skip to main content
. 2016 Dec 1;10:157–165. doi: 10.2147/BTT.S114625

Figure 5.

Figure 5

Mean (± standard deviation) cumulative cost of erythropoietic stimulating agents among patients initiated with originator and biosimilar products.

Note: p=0.065 (Kruskal–Wallis test).